Suchergebnisse - "Chamorey, Emmanuel"

PubPharm (15)

1

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

enthalten in: Oncoimmunology | 2020

von Montemagno, C. | Hagege, A. | Borchiellini, D. | +11

2

DPD status and fluoropyrimidines-based treatment : high activity matters too

enthalten in: BMC cancer | 2020

von Chamorey, E. | Francois, E. | Etienne, M. | +9

3

Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors

enthalten in: Investigational new drugs | 2020

von Refae, S. | Gal, J. | Ebran, N. | +7

ErratumIn: Invest New Drugs. 2021 Feb;39(1):287-292. - PMID 32500464

4

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2019

von Hofman, V. | Rouquette, I. | Long-Mira, E. | +18

5

Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer : A GETTEC multicentric study

enthalten in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2018

von Culié, D. | Garrel, R. | Viotti, J. | +16

6

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma

enthalten in: Theranostics | 2018

von Dufies, M. | Nollet, M. | Ambrosetti, D. | +20

7

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

enthalten in: British journal of cancer | 2017

von Dufies, M. | Giuliano, S. | Viotti, J. | +23

8

PD-L1 expression in basaloid squamous cell lung carcinoma : Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome

enthalten in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2016

von Ilie, M. | Falk, A. | Butori, C. | +12

9

Telomeric repeat-binding factor 2 : a marker for survival and anti-EGFR efficacy in oral carcinoma

enthalten in: Oncotarget | 2016

von Benhamou, Y. | Picco, V. | Raybaud, H. | +8

10

Trastuzumab and Cardiac Outcomes in Breast Cancer : A Story We Know by Heart?

enthalten in: JAMA oncology | 2016

von Milano, G. | Chamorey, E. | Ferrero, J.

CommentOn: JAMA Oncol. 2016 Jan;2(1):29-36. - PMID 26539793